How ECOPEACE uses autonomous robots and data to monitor and maintain urban water bodies.
Updated
January 8, 2026 6:27 PM
A school of fish swimming among debris and waste. PHOTO: UNSPLASH
South Korea–based water technology company ECOPEACE is working on a practical challenge many cities face today: keeping urban water bodies clean as pollution and algae growth become more frequent. Rather than relying on periodic cleanup drives, the company focuses on systems that can monitor and manage water conditions on an ongoing basis.
At the core of ECOPEACE’s work are autonomous water-cleanup robots known as ECOBOT. These machines operate directly on lakes, reservoirs and rivers, removing algae and surface waste while also collecting information about water quality. The idea is to combine cleaning with constant observation so changes in water conditions do not go unnoticed.
Alongside the robots, ECOPEACE uses a filtration and treatment system designed to process polluted water continuously. This system filters out contaminants using fine metal filters and treats the water using electrical processes. It also cleans itself automatically, which allows it to run for long periods without frequent manual maintenance.
The role of AI in this setup is largely about decision-making rather than direct control. Sensors placed across the water body collect data such as pollution levels and water quality indicators. The software then analyses this data to spot early signs of issues like algae growth. Based on these patterns, the system adjusts how the robots and filtration units operate, such as changing treatment intensity or water flow. In simple terms, the technology helps the system respond sooner instead of waiting for visible problems to appear.
ECOPEACE has already deployed these systems across several reservoirs, rivers and urban waterways in South Korea. Those projects have helped refine how the robots, sensors and software work together in real environments rather than controlled test sites.
Building on that experience, the company has begun expanding beyond Korea. It is currently running pilot and proof-of-concept projects in Singapore and the United Arab Emirates. These deployments are testing how the technology performs in dense urban settings where waterways are closely linked to public health, infrastructure and daily city life.
Both regions have invested heavily in smart city initiatives and water management, making them suitable test beds for automated monitoring and cleanup systems. The pilots focus on algae control, surface cleaning and real-time tracking of water quality rather than large-scale rollout.
As cities continue to grow and climate-related pressures on water systems increase, managing waterways is becoming less about occasional intervention and more about continuous oversight. ECOPEACE’s approach reflects that shift by using automation and data to address problems early and reduce the need for reactive cleanup later.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.